Skip to search formSkip to main contentSkip to account menu

ponatinib hydrochloride

Known as: Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)-, Hydrochloride (1:1) 
The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

Iclusig
Receptor Tyrosine Kinase Inhibitionponatinibponatinib 45 MG Oral Tablet [Iclusig]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Repurposing ponatinib for the treatment of colorectal cancer.
Review
2017
Review
2017
BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib
Dear Editor, BCR-ABL-positive acute myeloid leukemia (AML) represents less than 1 % of de novo AML that has been now recognized… 
2016
2016
Loss of SYK and LYN Tyrosine Kinase Expression Impair Ponatinib-Induced Apoptosis in K 562 Cells
Targeting the tyrosine kinase activity of BCR-ABL is the gold standard strategy in Chronic Myeloid Leukemia (CML) for the last… 
2016
2016
Evaluation of Efficacy and Safety of Ponatinib as Third-line Treatment in Patients with the Diagnosis of Chronic Phase Chronic Myeloid Leukemia
Philadelphia (Ph) is a fusion protein product of BCRABL and is a structurally active tyrosine kinase that causes chronic myeloid… 
2015
2015
EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
2014
2014
Ponatinib nel trattamento della leucemia
2014
2014
Abstract 3674: Targeted oncology therapeutics show unique cardiotoxic profiles: Ponatinib as a case study
Although tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis of multiple cancer types, unexpected… 
2013
2013
New concepts for CML clonality
BCR-ABL1 compound mutations, defined as ≥2 mutations within the same BCR-ABL1 allele, can confer high-level resistance to… 
2013
2013
Cancer Therapy : Preclinical See related commentary by Dao and Tyner , p . 1309 Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL 1 – Positive Leukemia
Purpose: The Hedgehog signaling pathway is a key regulator of cell growth and differentiation during development. Whereas the… 
2012
2012
Second-generation TKIs: which and when?
Impressive response rates and good tolerability have led imatinib 400 mg once a day to become the standard frontline therapy for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)